A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel; Pemetrexed
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 Jun 2017 Results (n=76; As of 30 Aug 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 May 2017 According to a Genentech media release, updated data from this phase Ib study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (2-6 Jun 2017), in Chicago.
    • 17 Mar 2017 Planned End Date changed from 1 Sep 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top